证券代码：603077 证券简称：和邦生物 公告编号：2024-093 四川和邦生物科技股份有限公司 向不特定对象发行可转换公司债券发行结果公告 保荐机构（主承销商）：首创证券股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 四川和邦生物科技股份有限公司（以下简称"发行人"或"公司"）公开发行 可转换公司债券（以下简称"可转债"）已获得中国证券监督管理委员会证监许可 〔2024〕1233 号文核准。首创证券股份有限公司（以下简称"首创证券"、"主承 销商"或"保荐人（主承销商）"）为本次发行的保荐机构（主承销商）。本次发行 的可转债简称为"和邦转债"，债券代码为"113691"。 | 类别 | 认购数量（手） | 放弃认购数量（手） | | --- | --- | --- | | 原股东 | 2,587,759 | 0 | | 网上社会公众投资者 | 1,939,826 | 72,415 | | 网下机构投资者 | - | - | | 主承销商包销数量（放弃 | | 72,415 | | 认购总数量 ...

根据上海证券交易所《上市公司自律监管指引第 3 号行业信息披露：第十三 号——化工》及相关要求，四川和邦生物科技股份有限公司（以下简称"公司"） 现将 2024 年 1-9 月主要经营数据披露如下： 一、主要产品的产量、销量及收入实现情况 | 主要产品 | 产量（吨） | 销量（吨） | 营业收入（万元） | | --- | --- | --- | --- | | 联碱化工类产品 | 1,950,818.85 | 1,172,241.94 | 143,345.37 | | 农药及中间体、副产品 | 201,297.77 | 182,034.43 | 241,621.01 | | 营养剂及中间体、副产品 | 122,115.48 | 126,343.48 | 87,378.17 | 注 1：联碱化工类产品包括：碳酸钠、氯化铵； 注 2：农药及中间体、副产品包括：双甘膦、草甘膦原粉、磷酸氢二钠等； 证券代码：603077 证券简称：和邦生物 公告编号：2024-092 四川和邦生物科技股份有限公司 2024 年 1-9 月主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥1,965,251,679.74, a decrease of 16.15% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥29,048,798.43, down 92.78% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥28,338,421.57, a decrease of 92.87% compared to the same period last year[2]. - The basic earnings per share for Q3 2024 was ¥0.0036, reflecting a decline of 92.19% year-on-year[4]. - The net profit for Q3 2024 was CNY 195,536,979.04, a significant decrease from CNY 1,014,075,433.12 in Q3 2023, representing a decline of approximately 80.7%[17]. - Operating profit for Q3 2024 was CNY 260,299,739.07, down from CNY 1,210,602,688.47 in the same period last year, indicating a decrease of about 78.5%[17]. - The company reported a total comprehensive income of CNY 162,460,496.75 for Q3 2024, a significant drop from CNY 1,014,013,688.94 in Q3 2023[18]. - Basic and diluted earnings per share for Q3 2024 were both CNY 0.0268, down from CNY 0.1168 in Q3 2023, reflecting a decrease of approximately 77%[18]. Assets and Liabilities - The total assets at the end of the reporting period were ¥25,975,312,679.92, an increase of 5.84% compared to the end of the previous year[4]. - The equity attributable to shareholders at the end of the reporting period was ¥18,764,699,737.51, a decrease of 4.14% compared to the end of the previous year[4]. - Total liabilities increased to CNY 6,594,523,781.89 from CNY 4,324,051,901.56, indicating a rise of about 52.5%[15]. - The company's equity attributable to shareholders decreased to CNY 18,764,699,737.51 from CNY 19,575,342,485.28, reflecting a decline of approximately 4.1%[15]. - Total assets reached CNY 25,975,312,679.92, up from CNY 24,542,434,122.85, representing a growth of approximately 5.8%[14]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥137,222,815.52, a decline of 192.91% year-on-year[2]. - Cash flow from operating activities showed a net outflow of CNY 137,222,815.52 in Q3 2024, contrasting with a net inflow of CNY 147,696,141.25 in Q3 2023[19]. - Net cash flow from investing activities was -$764.51 million, compared to -$672.36 million in the previous period[20]. - Cash inflow from financing activities totaled $2.87 billion, significantly up from $1.50 billion in the prior period[20]. - Net cash flow from financing activities was $367.71 million, a turnaround from -$299.20 million previously[20]. - Cash and cash equivalents at the end of the period amounted to $2.37 billion, down from $3.73 billion at the end of the previous period[20]. - The company experienced a net decrease in cash and cash equivalents of -$538.30 million, compared to -$810.11 million in the prior period[20]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 203,888[8]. - The largest shareholder, Sichuan Hebang Investment Group Co., Ltd., held 22.24% of the shares, amounting to 1,963,779,103 shares[8]. - The company reported a significant shareholder structure, with Sichuan Hebang Investment Group holding 1,963,779,103 shares, representing a substantial portion of the total shares[10]. - The company’s major shareholders include Sichuan Provincial Salt Industry Group and He Zhenggang, with significant ownership stakes contributing to the overall governance structure[10]. Operational Developments - The company has acquired a 7.6833% stake in Chongqing Heyou Industrial Co., Ltd., becoming one of its significant shareholders, to facilitate market integration in the soda ash and photovoltaic glass sectors[11]. - The company is nearing completion of the Guang'an Bimeda project, which aims for an annual production capacity of 500,000 tons of glyphosate, with large equipment procurement currently underway[11]. - The company has successfully obtained exploration rights for copper and lead-zinc mines in Xinjiang, signing contracts with the local natural resources department on September 14, 2024[11]. - The company is advancing the construction of the Indonesian project, having completed necessary investment registration and paid a 10% deposit for land acquisition[11]. - The company is in the final stages of the Ma Bian Yan Feng phosphate mine project, which is expected to commence production soon, while the Liujiashan phosphate mine project is progressing as planned[11]. - The company has engaged in market consolidation strategies through acquisitions, enhancing its operational capabilities and resource optimization[11]. Market and Future Outlook - Future outlook includes plans for market expansion and potential new product launches, aiming to leverage recent technological advancements in the biotech sector[16]. - The company reported a significant decrease in net profit due to macroeconomic impacts, including declines in product prices and sales volume[6]. Expenses - Total operating costs for the first three quarters of 2024 were CNY 6,550,036,297.80, up from CNY 5,261,021,840.03 in 2023, reflecting a significant increase in operational expenses[16]. - Research and development expenses decreased to CNY 22,518,887.99 in Q3 2024 from CNY 28,642,997.80 in Q3 2023, a reduction of approximately 21.5%[17]. - The total operating expenses rose to CNY 381,390,792.05 in Q3 2024, compared to CNY 339,168,812.71 in Q3 2023, an increase of approximately 12.5%[17]. - Financial expenses increased to CNY 32,109,142.20 in Q3 2024, compared to a financial income of CNY 7,095,986.15 in Q3 2023, indicating a shift of CNY 39,205,128.35[17]. - The company experienced a decrease in investment income, reporting a loss of CNY 463,137.97 in Q3 2024, down from a profit of CNY 45,317,746.40 in Q3 2023[17]. Accounting Standards - The company has adopted new accounting standards starting in 2024, which may affect financial reporting[21].

证券代码：603077 证券简称：和邦生物 公告编号：2024-091 凡参与和邦转债网上申购的投资者持有的申购配号尾数与上述号码相同的， 则为中签号码。中签号码共有 2,012,241 个，每个中签号码只能认购 1 手（1,000 元）和邦转债。 特此公告。 发行人：四川和邦生物科技股份有限公司 保荐人（主承销商）：首创证券股份有限公司 2024 年 10 月 30 日 网上中签结果公告 保荐人（主承销商）：首创证券股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《四川和邦生物科技股份有限公司向不特定对象发行可转换公司债券发 行公告》，发行人四川和邦生物科技股份有限公司、本次发行的保荐人（主承销 商）首创证券股份有限公司于 2024 年 10 月 29 日（T+1 日）主持了四川和邦生 物科技股份有限公司向不特定对象发行可转换公司债券（以下简称"和邦转债"） 网上发行中签摇号仪式。摇号仪式按照公开、公平、公正的原则在有关单位代表 的监督下进行，摇号结果经上海市东方公证处公证。现将中签结果公告如下： | 末尾 ...

Investment Rating - The report suggests a positive investment recommendation for HeBang Convertible Bonds, with an expected listing price range of 123.67 to 137.77 CNY on the first trading day, indicating a favorable market response [2][20][23]. Core Viewpoints - HeBang Bio is positioned as a leader in the glyphosate sector, leveraging its resource advantages in the Sichuan region to establish a robust industrial chain across chemicals, agriculture, and photovoltaic sectors [3][36]. - The company has shown steady revenue growth since 2019, with a compound annual growth rate (CAGR) of 10.27% from 2019 to 2023, despite a significant drop in revenue in 2023 [25][27]. - The convertible bond has a solid debt protection feature, with a current bond floor valuation of 97.55 CNY and a yield to maturity (YTM) of 2.41% [1][18]. Summary by Sections 1. Convertible Bond Basic Information - The total issuance scale of HeBang Convertible Bonds is 4.6 billion CNY, with net proceeds allocated to a glyphosate production project [1][15]. - The bond has a maturity period of 6 years, with a credit rating of AA/AA- from Zhongzheng Pengyuan [1][14]. 2. Investment Subscription Suggestions - The expected first-day trading price range for HeBang Convertible Bonds is between 123.67 and 137.77 CNY, with an anticipated subscription rate of 0.0214% [2][20][23]. 3. Underlying Stock Fundamental Analysis 3.1 Financial Data Analysis - HeBang Bio's revenue is primarily derived from the chemical industry, with a significant portion of its income coming from products like sodium carbonate and glyphosate [24][29]. - The company has diversified its product offerings and has established a strong market position in the glyphosate sector, with a focus on sustainable growth [3][36]. 3.2 Company Highlights - HeBang Bio has developed a resource-circulating industrial chain, enhancing its competitive edge in the southwestern region of China [3][36]. - The company has maintained stable sales and gross profit margins, with a notable decrease in sales expense ratios [4][33].

| --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：603077 证券简称：和邦生物 公告编号：2024-090 四川和邦生物科技股份有限公司 向不特定对象发行可转换公司债券 网上中签率及优先配售结果公告 保荐机构（主承销商）：首创证券股份有限公司 | 类别 | 中签率/配售 | 有效申购数量 | 实际配售数量 | 实际获配金额 | | --- | --- | --- | --- | --- | | | 比例（%） | （手） | （手） | （元） | | 原股东 | 100 | 2,587,759 | 2,587,759 | 2,587,759,000 | | 网上社会公众投资者 | 0.02407311 | 8,358,873,342 | 2,012,241 | 2,012,241,000 | | 网下机构投资者 | - | - | - | - | | 合计 | | 8,361,461,101 | 4,600,000 | 4,600,000,000 | 特别提示 四川和邦生物科技股份有限公司（以下简称"和邦生物"、"发行人"或"公 司"）向不特定对象发行可转换公司债券（以下简称"可转债"或"和邦转债"） 已获得中国证券监督管理委员会（以下简称" ...

证券代码：603077 证券简称：和邦生物 公告编号：2024-089 四川和邦生物科技股份有限公司 向不特定对象发行可转换公司债券发行提示性公告 保荐人（主承销商）：首创证券股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特别提示 四川和邦生物科技股份有限公司（以下简称"和邦生物"、"发行人"或"公 司"）向不特定对象发行可转换公司债券（以下简称"和邦转债"，债券代码 "113691"）已获得中国证券监督管理委员会（以下简称"中国证监会"）证监 许可〔2024〕1233 号文同意注册。公司聘请首创证券股份有限公司（以下简称 "首创证券"、"保荐人（主承销商）"或"主承销商"）担任本次发行的主承 销商。投资者可在上海证券交易所网站（http://www.sse.com.cn）查询《四川和邦 生物科技股份有限公司向不特定对象发行可转换公司债券募集说明书》（以下简 称"《募集说明书》"）全文及本次发行的相关资料。 公司根据《中华人民共和国证券法》、《上市公司证券发行注册管理办法》 （证监会令[第 206 号]）、《证 ...

四川和邦生物科技股份有限公司向不特定 对象发行可转换公司债券信用评级报告 CSCI Pengyuan Credit Rating Report 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人 员与评级对象不存在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告 遵循了真实、客观、公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的 合法性、真实性、准确性和完整性作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组 织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、 持有任何证券的建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导 致的任何损失负责。 中证鹏元资信评估股份有限公司 地址：深圳市深南大道 7008 号阳光高尔夫大厦三楼 电话: 0755-82872897 传真：0755-82872090 邮编: 518040 网址：www.cspengyuan.com 中鹏信评【2024】第 Z ...

证券代码：603077 证券简称：和邦生物 公告编号：2024-087 本次会议由本期员工持股计划管理委员会主任王军先生主持，会议的召集、 召开和表决程序符合相关规定。经与会持有人认真讨论，审议通过了如下议案： 一、审议通过《本期员工持股计划参与公司发行可转债原股东配售的议案》 公司可转债发行上市工作正在加快推进。根据上海证券交易所关于可转换公 司债券发行与承销业务的相关规定，原股东享有优先配售权。为坚定本期员工持 股计划对公司长期发展的战略信心，同时更好地践行与股东、公司"价值共创、 利益共享、风险共担"机制，同意本期员工持股计划参与公司本次发行可转债的 原股东配售，具体事宜（包括但不限于根据资金情况确定参与配售金额、提出并 实施资金解决方案、出资、配售可转债、处置等）授权管理委员会办理。 表决结果：同意42,633.51万份，反对0.00万份，弃权0.00万份。 特此公告。 四川和邦生物科技股份有限公司董事会 四川和邦生物科技股份有限公司 第二期员工持股计划第二次持有人会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律 ...